Evidence map›Paper›PMID 35242721›Full record

ReviewFrontiers in cellular and infection microbiology2022

Gut Microbiota: An Important Player in Type 2 Diabetes Mellitus.

Zheng Zhou, Bao Sun, Dongsheng Yu, Chunsheng Zhu

Registry-linked trialOpen access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in cellular and infection microbiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07124585 (Short-Term Effect of Non-Nutritive Sweeteners), which is not on this map. Cited by 189 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
189citing papers in PubMed, 7 pooled it
23.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07124585 nanot yet recruitingnot on this mapstarted 2026, after this paper: background citation

Short-Term Effect of Non-Nutritive Sweeteners (Sucralose and Saccharin) Consumption on Glycaemic Control and Gut Microbiota in Type 2 Diabetes Patients

TypeinterventionalSponsorNational University of MalaysiaRan2026 to 2027Enrolled33ConditionsType 2 Diabetes Mellitus (T2DM)ArmsSucralose, Saccharin, Placebo (Calcium Carbonate)
3 · Its place in the literature

Who cites it

189 citing papers in PubMed, 7 syntheses or guidelines pooled it, 296 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Article
  20. Article

129 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Zheng ZhouDepartment of Chinese Medicine, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Bao SunDepartment of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha, China.
Dongsheng YuDepartment of Chinese Medicine, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Chunsheng ZhuDepartment of Chinese Medicine, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
First Affiliated Hospital of Zhengzhou University · CNCentral South University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Type 2 diabetes mellitus (T2DM) is one of the common metabolic diseases in the world. Due to the rise in morbidity and mortality, it has become a global health problem. To date, T2DM still cannot be cured, and its intervention measures mainly focus on glucose control as well as the prevention and treatment of related complications. Interestingly, the gut microbiota plays an important role in the development of metabolic diseases, especially T2DM. In this review, we introduce the characteristics of the gut microbiota in T2DM population, T2DM animal models, and diabetic complications. In addition, we describe the molecular mechanisms linking host and the gut microbiota in T2DM, including the host molecules that induce gut microbiota dysbiosis, immune and inflammatory responses, and gut microbial metabolites involved in pathogenesis. These findings suggest that we can treat T2DM and its complications by remodeling the gut microbiota through interventions such as drugs, probiotics, prebiotics, fecal microbiota transplantation (FMT) and diets.

Indexed as

Diabetes Mellitus, Type 2Gastrointestinal MicrobiomeProbioticsAnimalsDysbiosisFecal Microbiota TransplantationPrebioticsPrebioticsglucose metabolismgut microbiotainsulin resistancepathogenesistype 2 diabetes mellitus

Identifiers

PMID35242721
PMCPMC8886906
OpenAlexW4213202281

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.